AML: Cellectis testing allogenic CAR-T cell therapy – European Biotechnology
European Biotechnology |
AML: Cellectis testing allogenic CAR–T cell therapy
European Biotechnology While Novartis AG and Kite Pharma are leading the CAR–T cell therapy development in AML, Cellectis hopes to overtake its competitors. It has the only approach that works with allogenic CAR-engineered T cells that could be centrally pre-manufactured in … |
